Regional anesthesia

Comparison of pericapsular nerve group and lateral quadratus lumborum blocks on cumulative opioid consumption after primary total hip arthroplasty: a randomized controlled trial

Reg Anesth Pain MedPublished Randomised controlled trial

Authors' conclusion

While both lateral QLB and PENG block+LFC block are effective analgesic methods for patients undergoing THA, patients receiving lateral QLB had decreased cumulative opioid consumption from 36 to 72 hours postoperative and lower pain scores with movement compared with patients receiving PENG+LFC blocks.

Study context

Population
Patients scheduled for elective primary total hip arthroplasty101 analysed
Participants
106 patients
Comparison
Lateral quadratus lumborum block (QLB) vs pericapsular nerve group (PENG) block + lateral femoral cutaneous nerve block
  • QLBn = 51
  • PENGn = 50reference
Primary endpoint
Postoperative cumulative opioid consumption measured over time
Follow-up
Up to 72 hours
Methodological detailssuperiority, Standardized perioperative analgesic protocols
  • Superiority
  • Standardized perioperative analgesic protocols

Primary result

As reported in the abstract

Cumulative opioid consumption (IV morphine milligram equivalents) · 36–72 hours

Mean difference at 36 h

18.0

95% CI 0.80, 35.1p=0.040

Mean difference at 48 h

23.0

95% CI 5.20, 40.8p=0.011

Mean difference at 60 h

28.0

95% CI 9.24, 46.7p=0.004

Mean difference at 72 h

33.0

95% CI 13.0, 53.0p=0.001

Secondary outcomes

Average resting pain score, time to ambulation, same-day discharge, LOS, patient-reported functional outcomes

No significant differences between treatment arms

Original publication

Comparison of pericapsular nerve group and lateral quadratus lumborum blocks on cumulative opioid consumption after primary total hip arthroplasty: a randomized controlled trial. Reg Anesth Pain Med. Published 10 October 2024. doi:10.1136/rapm-2024-105875

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.